To promote the work of its member centers, AACI publishes Commentary, an editorial series focusing on major issues of common interest to North American cancer centers.
Each AACI Commentary is written by a cancer center leader or subject matter expert and distributed by email to over 3,500 subscribers of the AACI Update newsletter.
The publication is designed to cover a specific topic in 750-1,000 words. Recommendations for topics and authors are encouraged.
On June 15, AACI jointly hosted the 2022 virtual Hill Day with the American Association for Cancer Research (AACR). During 87 meetings with legislators, cancer center directors, researchers, physician-scientists, cancer survivors, and other advocates made the case for robust, sustained federal investments in biomedical research—and cancer research in particular—through the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
For Fiscal Year (FY) 2023, AACI is advocating for an increase of $4.1 billion for the NIH. We are also asking Congress to provide at least $7.766 billion—a roughly $850 million increase—for the NCI in FY 2023, in line with the NCI director’s professional judgment budget.
These increases are especially important now, in light of President Joe Biden’s focus on the ARPA-H and Cancer Moonshot 2.0 initiatives and ongoing concerns regarding the discrepancy between the percentage of research grants funded by the NCI and that of other NIH institutes.
2022 AACI/AACR Hill Day Highlights Importance of Strong Funding, Continued Advocacy
By Jaren Love
Driving Change in Lung Cancer: Cancer Centers Must Ensure That Lung Screening Reaches Those Who Can Benefit Most
By Candace S. Johnson, PhD
Marketing and the Physician Outreach Team
By Erin McElwain, MHA, and Heidi Findlay
Repairing Damage to Clinical Trials Office Staffing
By Kristie Moffett
Our Best Defense Against Cancer: Robust Funding is Essential to Continued Research Progress
By Roy A. Jensen, MD